Form D · Pharmaceuticals

AbbVie Inc.

North Chicago, IL · CIK 0001551152

Offering snapshot reported May 9, 2016 · SEC filing

Reported sold
$3.8B
Offering amount: $3.8B
Investors reported
39
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 25, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 9, 2016Initial$3,800,000,000No comparison39SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-262797
AbbVie Inc. will issue 62.5 million shares of AbbVie common stock in the transaction. The total offering amount is calculated based on a fixed value of $60.664 per share.

Source: Form D, filed May 9, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Carlos Alban Executive
Robert J. Alpern Director
Roxanne S. Austin Director
William H.L. Burnside Director
William J. Chase Executive
Richard A. Gonzalez Director, Executive
Henry Gosebruch Executive
Brett J. Hart Director
Thomas A. Hurwich Executive
Edward M. Liddy Director
Edward J. Rapp Director
Timothy J. Richmond Executive
Azita Saleki Gerhardt Executive
Laura J. Schumacher Executive
Michael E. Severino Executive
Glenn F. Tilton Director
Frederick H. Waddell Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1 North Waukegan Road
North Chicago, IL, 60064-6400